Journal of Hepatology
Volume 48 , Pages S93-S103 , 2008

Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis

  • Paolo Angeli

      Affiliations

    • These authors equally contributed to this manuscript.
    • ,
  • Carlo Merkel

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39 049 8212282; fax: +39 049 8754179.
    • These authors equally contributed to this manuscript.

References 

  1. Helvig FC, Schutz CB. A liver and kidney syndrome: clinical, pathological, and experimental studies. Surg Gynecol Obstet. 1932;55:570–582
  2. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet. 1956;2:1121–1129
  3. Papper S. The hepato-renal syndrome. Clin Nephrol. 1975;4:41–54
  4. Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepato-renal syndrome: evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med. 1969;280:1367–1371
  5. Epstein M, Berk DP, Hollenberg NK, Adams DF, Chalmers TC, Abrams HL, et al. Renal failure in the patient with cirrhosis. The role of active vasoconstriction. Am J Med. 1970;49:175–185
  6. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepato-renal syndrome in cirrhosis. Hepatology. 1996;23:164–176
  7. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of the hepato-renal syndrome in cirrhosis. Gut. 2007;56:1310–1318
  8. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312:1604–1608
  9. Moreau R, Lebrec D. Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology. 2003;37:233–243
  10. Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors and prognosis of the hepato-renal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229–236
  11. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arteriolar vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151–1157
  12. Gines P, Guevara M, Arroyo V, Rodes J. Hepato-renal syndrome. Lancet. 2003;362:1819–1827
  13. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20:1495–1501
  14. Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, et al. Switch therapy with ciprofloxacin versus intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis:similar efficacy at lower cost. Alimentary Pharmacol Ther. 2006;23:75–84
  15. Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45:223–229
  16. Terra C, Guevara M, Torre A, Gilabert R, Fernandez J, Martin-Llahi M, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology. 2005;129:1944–1953
  17. Arroyo V, Planas R, Gaya J, Deulofeu J, Rimola A, Perez-Ayuso RM, et al. Sympathetic nervous activity, renin–angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest. 1983;13:271–278
  18. Henriksen JH, Ring-Larsen H. Hepato-renal disorders: role of the sympathetic nervous system. Sem Liver Dis. 1994;14:35–43
  19. Gentilini P, Romanelli RG, La Villa G, Maggiore Q, Pesciullesi E, Cappelli G, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology. 1993;104:588–594
  20. Solis-Herruzo JA, Duran A, Favela V, Castellano G, Madrid JL, Munoz-Yague MT, et al. Effects of lumbar sympathetic block on kidney function in cirrhotic patients with hepato-renal syndrome. J Hepatol. 1987;5:167–173
  21. Piscaglia F, Zironi G, Gaiani S, Ferlito M, Rapezzi C, Siringo S, et al. Relationship between splanchnic, peripheral and cardiac haemodynamics in liver cirrhosis of different degrees of severity. Eur J Gastroenterol Hepatol. 1997;9:799–804
  22. Fernandez-Seara J, Prieto J, Quiroga J, Zozaia JM, Cobos MA, Rodriguez-Eire JL, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology. 1989;97:1304–13012
  23. Maroto A, Gines P, Arroyo V, Gines A, Salò J, Claria J, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology. 1993;17:788–793
  24. Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Renal vasoconstriction in cirrhosis evaluated by duplex ultrasonography. Hepatology. 1993;17:219–224
  25. Dillon JF, Plevris JN, Wong FC, Chan KH, Lo NT, Miller JD, et al. Middle cerebral artery blood flow velocity in patients with cirrhosis. Eur J Gastroenterol Hepatol. 1995;7:1087–1091
  26. Rivolta R, Maggi A, Cazzaniga M, Castagnone D, Panzeri A, Solenghi D, et al. Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology. 1998;28:1235–1240
  27. Guevara M, Bru C, Gines P, Fernadez-Esparrach G, Sort P, Bataller R, et al. Increased cerebrovascular resistance in cirrhotic patients with ascites. Hepatology. 1998;28:39–44
  28. Sugano S, Yamamoto K, Atobe T, Watanabe M, Vakui N, Iwasaki N, et al. Postprandial middle cerebral arterial vasoconstriction in cirrhotic patients. A placebo controlled evaluation. J Hepatol. 2001;34:373–377
  29. Moller S, Henriksen J. The systemic circulation in cirrhosis. In:  Gines P,  Arroyo V,  Rodes J,  Schrier RW editor. Ascites and renal dysfunction in liver disease. II ed.. Blackwell Publ.; 2005;p. 139–155
  30. Luca A, Garcia-Pagan JC, Feu F, Lopez-Talavera JC, Fernandez M, Bru C, et al. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology. 1995;21:83–88
  31. Carella M, Hunter JO, Fazio S, Dela Piano C, Bartoli GC. Capillary blood flow in the skin of forearm in cirrhosis. Angiology. 1992;43:969–974
  32. Newby DE, Jalan R, Masumori S, Hayes PC, Boon NA, Webb DJ. Peripheral vascular tone in patients with cirrhosis: role of the rennin–angiotensin and sympathetic nervous systems. Cardiovasc Res. 1998;38:223–228
  33. Angeli P, Albino G, Carraro P, Dalla Pria M, Merkel C, Caregaro L, et al. Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology. 1996;23:264–273
  34. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology. 2002;35:478–491
  35. Bolognesi M, Sacerdoti D, Piva A, Di Pascoli M, Zampieri F, Quarta S, et al. Carbon monoxide-mediated activation of large conductance calcium-activated potassium channels contributes to mesenteric vasodilation in cirrhotic rats. J Pharmacol Exp Ther. 2007;321:187–194
  36. Sieber CC, Mosca PG, Groszmann RJ. Effect of somatostatin on mesenteric vascular resistance in normal and portal hypertensive rats. Am J Physiol. 1992;262:G274–G277
  37. Fernandez M, Garcia-Pagan JC, Casadevall M. Acute and chronic cyclooxygenase blockade in portal-hypertensive rats: influence on nitric oxide biosynthesis. Gastroenterology. 1998;110:1529–1535
  38. Guevara M, Gines P, Jimenez W, Sort P, Fernandez-Esparrach G, Escorsell A, et al. Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology. 1998;114:336–343
  39. Ros J, Claria J, To-Figueras J, Planagumà A, Cejudo-Martı`n P, Fernandez-Varo G, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology. 2002;122:85–93
  40. Angeli P, Fernandez-Varo G, Dalla Libera V, Fasolato S, Galioto A, Arroyo V, et al. The role of nitric oxide in the pathogenesis of systemic and splanchnic vasodilation in cirrhotic rats before and after the onset of ascites. Liver. 2005;29:429–437
  41. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of an oral administration of midodrine an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998;28:937–943
  42. Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest. 1967;46:1894–1906
  43. Lebrec D, Kotelanski B, Cohn JN. Splanchnic hemodynamic factors in cirrhosis with refractory ascites. J Lab Clin Med. 1979;93:301–309
  44. Henriksen JH. Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis. Scand J Clin Invest. 2004;64:523–534
  45. Ruiz del Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal and hepatic haemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38:1210–1218
  46. Ruiz del Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepato-renal syndrome. Hepatology. 2005;42:439–447
  47. Tsai MH, Peng YS, Chen YC, Liu NI, Ho YP, Fang JT, et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology. 2006;43:673–681
  48. Fernandez J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology. 2006;44:1288–1295
  49. Ma ZH, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology. 1996;24:451–459
  50. Bresing KA, Textor J, Perez J, Schidermeier P, Raab P, Strunk H, et al. Long-term outcome after transjugular intrahepatic portosystemic stent–shunt in non-transplant cirrhotics with hepato-renal syndrome: a phase II study. Gut. 2000;47:288–295
  51. Soper CPR, Latif AB, Bendino MR. Amelioration of hepato-renal syndrome with selective endothelin-A antagonist. Lancet. 1996;347:1842–1843
  52. Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with non selective endothelin antagonism with tezosentan in type 2 hepato-renal syndrome. Hepatology. 2008;47:160–168
  53. Rimola A, Gines P, Arroyo V, Camps J, Perez-Ayuso RM, Quintero E, et al. Urinary excretion of 6-keto-prostaglandin F1α, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. J Hepatol. 1986;3:111–117
  54. Zipster RD, Radvan GH, Kronborg IJ, Duke R, Little TE. Urinary thromboxane B2 and prostaglandin E2 in the hepato-renal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology. 1983;84:697–703
  55. Moore KP, Taylor GW, Maltby NH, Siegers D, Fuller RW, Dollerty CT, et al. Increased production of cysteinyl leukotrienes in hepato-renal syndrome. J Hepatol. 1990;11:263–271
  56. Sacerdoti D, Balazy M, Angeli P, Gatta A, McGiff JC. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest. 1997;100:1264–1270
  57. Ros J, Claria J, Jimenez W, Bosch-Marcè M, Angeli P, Arroyo V, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology. 1995;22:915–920
  58. Angeli P, Jimenez W, Arroyo V, Mackenzie HS, Zang PL, Cları`a J, et al. Renal effects of endogenous natriuretic peptides receptors blockade in cirrhotic rats with ascites. Hepatology. 1994;20:948–954
  59. Laffi G, Daskalopoulos G, Kronborg I, Hsueh W, Gentilini P, Ziepser RD. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology. 1986;90:182–187
  60. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation. 1995;59:361–365
  61. Navasa M, Feu F, Garcia-Pagan JC, Jimenez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver-transplantation in patients with cirrhosis. Hepatology. 1993;17:355–360
  62. Schlitt HJ, Barkmann A, Boeker KH, Schmidt HH, Enmanoulidis N, Rosenau J, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet. 2001;357:587–591
  63. Restuccia T, Ortega R, Guevara M, Gines P, Alessandria C, Ozdogan O, et al. Effects of treatment of hepato-renal syndrome before transplantation on posttransplantation outcome. A case control study. Liver Transpl. 2004;40:140–146
  64. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jiménez W, et al. Transjugular intrahepatic portosystemic shunt in hepato-renal syndrome: effects on renal function and vasoactive systems. Hepatology. 1998;28:416–422
  65. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepato-renal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology. 1998;27:35–41
  66. Gilberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepato-renal syndrome type 1 with ornipressin and albumin. Hepatology. 1999;30:870–875
  67. Ganne-Carrie N, Hadegue A, Mathurin P, Durand F, Erlinger S, Benhamou JP. Hepato-renal syndrome: long-term treatment with terlipressin as bridge to liver transplantation. Dig Dis Sci. 1996;41:1054–1056
  68. Le Moine O, El Nawar A, Jagodzinski R, Burgeois N, Adler M, Gelin M, et al. Treatment with terlipressin as a bridge to transplantation in a patient with hepato-renal syndrome. Acta Gastroenterol Belg. 1998;61:268–270
  69. Duhamel C, Mauillon J, Berkelmans J, Bourienne A, Tranvuez JL. Hepato-renal syndrome in cirrhotic patients: terlipressin is a safe and efficient treatment; propranolol and digitalic treatment: precipitating and preventing factors?. Am J Gastroenterol. 2000;95:2984–2985
  70. Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, et al. Effect of terlipressin (glypressin) on hepato-renal syndrome in cirrhotic patients: results of a multicenter pilot study. Eur J Gastroenterol Hepatol. 2002;14:153–158
  71. Mulkay JP, Louis H, Donckier V, Burgeois N, Adler M, Deviere J, et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepato-renal syndrome: a pilot study. Acta Gastroelerologica Belg. 2001;64:15–19
  72. Uriz J, Gines P, Cardenas A, Sort P, Jimenez W, Salmeron JM, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepato-renal syndrome. J Hepatol. 2000;33:43–48
  73. Ortega R, Gines P, Uriz J, Cardenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepato-renal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941–948
  74. Solanki P, Chawala A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepato-renal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18:152–156
  75. Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichai P, et al. Terlipressin in patients with cirrhosis and type 1 hepato-renal syndrome: a retrospective multicenter study. Gastroenterology. 2002;122:923–930
  76. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepato-renal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology. 1999;29:1690–1697
  77. Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barriere E, et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepato-renal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol. 2002;17:882–888
  78. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepato-renal syndrome. Hepatology. 2004;40:55–64
  79. Esrailian E, Pantageo ER, Kyulo NL, Hu KQ, Runyon BA. Octretide/midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepato-renal syndrome. Dig Dis Sci. 2007;52:742–748
  80. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type 1 hepato-renal syndrome: a pilot study. Hepatology. 2002;36:374–380
  81. Arroyo V, Terra C, Gines P. Advances in the pathogenesis and treatment of type 1 and type 2 hepato-renal syndrome. J Hepatol. 2007;46:935–936
  82. Sanyal A, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Teuber P, et al. A prospective randomized double blind placebo-controlled trial of terlipressin for Type 1 hepato-renal syndrome (HRS). Hepatology. 2006;44:494A
  83. Martin-Llahi M, Pepin MN, Guevara M, Torre A, Monescillo A, Soriano G, et al. Randomized comparative study of terlipressin and albumin vs albumin alone in patients with cirrhosis and hepato-renal syndrome. J Hepatol. 2007;46:S36
  84. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepato-renal syndrome with extracorporeal albumin dialysis MARS: results on a prospective, randomized controlled clinical trial. Liver Transpl. 2000;6:277–286
  85. Angeli P. Review article: prognosis of hepato-renal syndrome – has it changed with current practice?. Aliment Pharmacol Ther. 2004;20:1–4
  86. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites. J Hepatol. 1996;25:135–144
  87. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Eng J Med. 2000;342:1700–1707
  88. Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath PS, Ruiz del Arbol L, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002;123:1839–1847
  89. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American Study for the treatment of refractory ascites. Gastroenterology. 2003;124:634–641
  90. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:629–635
  91. Saab S, Nieto JM, Ly D, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev. 2004;3:CD004889
  92. D’Amico G, Luca A, Morabito A, Miraglia R, D’Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology. 2005;129:1282–1293
  93. Salerno F, Cammà C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133:825–834
  94. Alessandria C, Venon WD, Marzano A, Barletti C, Fadda M, Rizzetto M. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepato-renal syndrome type 2. Eur J Gastroenterol Hepatol. 2002;14:1363–1368
  95. Fernandez J, Navasa M, Planas R, Montoliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepato-renal syndrome and improves survival in cirrhosis. Gastroenterology. 2007;133:818–824
  96. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz del Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409
  97. Fernandez J, Navasa M, Garcia-Pagan JC, Abraldes J, Jimenez W, Bosch J, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol. 2004;41:384–390
  98. Evans TW. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002;16:6–11

☆ The authors declare that they do not have anything to disclose regarding industry funding or conflict of interest with respect to this manuscript. The authors declare that they received funding from the University of Padova and the Italian Ministry for University and Research.

PII: S0168-8278(08)00056-1

doi: 10.1016/j.jhep.2008.01.010

Journal of Hepatology
Volume 48 , Pages S93-S103 , 2008

Article Tools

* Image Usage & Resolution